Literature DB >> 33254539

Olfactory dysfunction may predict myocardial injury in COVID-19 patients.

Ercan Akşit1, Özge Çağlar Çil2, Hakkı Kaya3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33254539      PMCID: PMC7467065          DOI: 10.1016/j.mehy.2020.110232

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


× No keyword cloud information.
As a hypothesis, in the coronavirus disease 2019 (COVID-19) pandemic, growing evidence suggests a possible correlation between increased cytokine levels, olfactory dysfunction and myocardial injury. Puntmann et al. studied the cardiovascular magnetic resonance imaging of patients who survived COVID-19 and showed that 78% of the patients had cardiac involvement, and even if the disease had healed, 60% continued to have myocardial inflammation [1]. Haehner et al. showed that 64.7% of COVID-19 patients had ‘sudden smell loss’ [2]. In their autopsy study, Solomon et al. reported that there was no damage to olfactory bulbs or tracts of COVID-19 patients [3] whereas Torabi et al. reported significant increase in local tumour necrosis factor alpha (TNF-α) levels of the olfactory epithelium in COVID-19 patients [4]. Based on this, it has been observed that covid-19 disease has more frequent occurrence of sudden olfactory dysfunction than other flu diseases, cardiac involvement and thrombogenic events are more frequent, and it is a ‘cytokine storm’ since the first symptom phase. In addition we showed a direct relationship between the severity of heart failure and that of olfactory dysfunction. An important hypothesis explaining this clinical relationship is that TNF-α and interleukin-1 (IL-1) levels increase in heart failure patients and in those with olfactory dysfunction [5]. Considering this literature and two important recent studies, the similarity between the frequency of cardiac involvement (78%) and that of sudden smell loss (64.7%) in COVID-19 patients suggests that olfactory dysfunction in COVID-19 patients can be a predictor of myocardial injury. When olfactory dysfunction is detected in COVID-19 patients, providing optimal primary and secondary cardiovascular prevention can positively contribute to the disease course.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  5 in total

1.  Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia.

Authors:  Abolfazl Torabi; Esmaeil Mohammadbagheri; Nader Akbari Dilmaghani; Amir-Hossein Bayat; Mobina Fathi; Kimia Vakili; Rafieh Alizadeh; Omidvar Rezaeimirghaed; Mohammadreza Hajiesmaeili; Mahtab Ramezani; Leila Simani; Abbas Aliaghaei
Journal:  ACS Chem Neurosci       Date:  2020-06-11       Impact factor: 4.418

2.  Predictive Value of Sudden Olfactory Loss in the Diagnosis of COVID-19.

Authors:  Antje Haehner; Julia Draf; Sarah Dräger; Katja de With; Thomas Hummel
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2020-06-11       Impact factor: 1.538

3.  Olfactory Dysfunction in Patients with Ischemic Heart Failure.

Authors:  Ercan Akşıt; Özge Çağlar Çıl
Journal:  Acta Cardiol Sin       Date:  2020-03       Impact factor: 2.672

4.  Neuropathological Features of Covid-19.

Authors:  Isaac H Solomon; Erica Normandin; Shamik Bhattacharyya; Shibani S Mukerji; Kiana Keller; Ahya S Ali; Gordon Adams; Jason L Hornick; Robert F Padera; Pardis Sabeti
Journal:  N Engl J Med       Date:  2020-06-12       Impact factor: 91.245

5.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).

Authors:  Valentina O Puntmann; M Ludovica Carerj; Imke Wieters; Masia Fahim; Christophe Arendt; Jedrzej Hoffmann; Anastasia Shchendrygina; Felicitas Escher; Mariuca Vasa-Nicotera; Andreas M Zeiher; Maria Vehreschild; Eike Nagel
Journal:  JAMA Cardiol       Date:  2020-11-01       Impact factor: 14.676

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.